EP3359039A4 - Medizinische anordnungen und verfahren zur bestimmung von parametern bezüglich einer insulintherapie, vorhersage von glucosewerten und zur bereitstellung von insulindosierungsempfehlungen - Google Patents

Medizinische anordnungen und verfahren zur bestimmung von parametern bezüglich einer insulintherapie, vorhersage von glucosewerten und zur bereitstellung von insulindosierungsempfehlungen Download PDF

Info

Publication number
EP3359039A4
EP3359039A4 EP16853994.8A EP16853994A EP3359039A4 EP 3359039 A4 EP3359039 A4 EP 3359039A4 EP 16853994 A EP16853994 A EP 16853994A EP 3359039 A4 EP3359039 A4 EP 3359039A4
Authority
EP
European Patent Office
Prior art keywords
insulin
parameters related
glucose values
determining parameters
providing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP16853994.8A
Other languages
English (en)
French (fr)
Other versions
EP3359039B1 (de
EP3359039A1 (de
Inventor
Fredrik STÅHL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dianovator AB
Original Assignee
Dianovator AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dianovator AB filed Critical Dianovator AB
Publication of EP3359039A1 publication Critical patent/EP3359039A1/de
Publication of EP3359039A4 publication Critical patent/EP3359039A4/de
Application granted granted Critical
Publication of EP3359039B1 publication Critical patent/EP3359039B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
EP16853994.8A 2015-10-09 2016-10-07 Medizinische anordnungen und verfahren zur bestimmung von parametern bezüglich einer insulintherapie, vorhersage von glucosewerten und zur bereitstellung von insulindosierungsempfehlungen Active EP3359039B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1530154 2015-10-09
PCT/SE2016/050966 WO2017061943A1 (en) 2015-10-09 2016-10-07 Medical arrangements and a method for determining parameters related to insulin therapy, predicting glucose values and for providing insulin dosing recommendations

Publications (3)

Publication Number Publication Date
EP3359039A1 EP3359039A1 (de) 2018-08-15
EP3359039A4 true EP3359039A4 (de) 2019-05-15
EP3359039B1 EP3359039B1 (de) 2021-07-14

Family

ID=58488018

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16853994.8A Active EP3359039B1 (de) 2015-10-09 2016-10-07 Medizinische anordnungen und verfahren zur bestimmung von parametern bezüglich einer insulintherapie, vorhersage von glucosewerten und zur bereitstellung von insulindosierungsempfehlungen

Country Status (6)

Country Link
US (1) US20180296142A1 (de)
EP (1) EP3359039B1 (de)
CN (1) CN108289642B (de)
CA (1) CA3001448A1 (de)
WO (1) WO2017061943A1 (de)
ZA (1) ZA201802977B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46048A (fr) 2016-08-25 2019-07-03 Novo Nordisk As Kit de débutant pour le titrage de l'insuline de base
US11295847B2 (en) * 2016-08-26 2022-04-05 Novo Nordisk A/S Systems and methods for adjusting basal administration timing
CN110012675B (zh) * 2016-11-29 2024-02-27 诺和诺德股份有限公司 用于基础率滴定的起始套件
CN107137093B (zh) * 2017-04-20 2019-06-07 浙江大学 一种包含异常血糖概率报警器的连续血糖监测设备
EP3857557A1 (de) * 2018-09-24 2021-08-04 Novo Nordisk A/S System zur erhöhung der datenqualität von ausgegebenen datensätzen
CN113539403A (zh) * 2021-07-16 2021-10-22 上海市公共卫生临床中心 一种基于规则的胰岛素追加剂量计算方法
US20230402149A1 (en) * 2022-05-19 2023-12-14 Insulet Corporation Switching and customization of glucose prediction models in medicament delivery devices

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272640A1 (en) * 2004-05-13 2005-12-08 Doyle Francis J Iii Method and apparatus for glucose control and insulin dosing for diabetics
US8818782B2 (en) * 2007-06-27 2014-08-26 Roche Diagnostics Operations, Inc. System for developing patient specific therapies based on dynamic modeling of patient physiology and method thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8480580B2 (en) * 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US20050203001A1 (en) * 2004-03-05 2005-09-15 Emisphere Technologies, Inc. Oral insulin therapies and protocol
US20070276197A1 (en) * 2006-05-24 2007-11-29 Lifescan, Inc. Systems and methods for providing individualized disease management
ES2330897T3 (es) * 2007-01-29 2009-12-16 F. Hoffmann-La Roche Ag Procedimiento de evaluacion para el procesamiento de una señal de concentracion en glucosa.
EP2891885A3 (de) * 2007-04-18 2015-10-14 Health Diagnostic Laboratory, Inc. Diabetesassoziierte Biomarker und Verfahren zu deren Verwendung
JP2010525335A (ja) * 2007-04-20 2010-07-22 ベリデックス・エルエルシー インスリン感受性及びブドウ糖吸収の判定方法
US20100145262A1 (en) * 2007-05-03 2010-06-10 Novo Nordisk A/S Safety system for insulin delivery advisory algorithms
US20100198520A1 (en) * 2007-07-09 2010-08-05 University Of Virginia Patent Foundation Method, System and Computer Program Product for Evaluation of Insulin Sensitivity, Insulin/Carbohydrate Ratio, and Insulin Correction Factors in Diabetes from Self-Monitoring Data
EP2023256A1 (de) * 2007-08-02 2009-02-11 Novo Nordisk A/S Überwachung von Arzneimittelverabreichung
US20090143725A1 (en) * 2007-08-31 2009-06-04 Abbott Diabetes Care, Inc. Method of Optimizing Efficacy of Therapeutic Agent
EP4159114B1 (de) * 2007-10-09 2024-04-10 DexCom, Inc. Integriertes insulin-abgabesystem mit kontinuierlichem glucosesensor
WO2009059187A1 (en) * 2007-11-02 2009-05-07 University Of Virginia Patent Foundation Predictive control based system and method for control of insulin delivery in diabetes using glucose sensing
US20100138203A1 (en) * 2008-02-12 2010-06-03 Alferness Clifton A System and method for actively managing type 2 diabetes mellitus on a personalized basis
US20100198020A1 (en) * 2008-02-12 2010-08-05 Alferness Clifton A System And Method For Computer-Implemented Method For Actively Managing Increased Insulin Resistance In Type 2 Diabetes Mellitus
US9341614B2 (en) * 2008-04-04 2016-05-17 Hygieia, Inc. Apparatus and methods for taking blood glucose measurements and recommending insulin doses
US8527208B2 (en) * 2008-11-17 2013-09-03 Roche Diagnostics International Ag Prandial blood glucose excursion optimization method via computation of time-varying optimal insulin profiles and system thereof
US10478100B2 (en) * 2009-02-04 2019-11-19 Sanofi-Aventis Deutschland Gmbh Medical system and method for providing information for glycemic control
US8562587B2 (en) * 2009-02-25 2013-10-22 University Of Virginia Patent Foundation CGM-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction of insulin delivery
JP2012519018A (ja) * 2009-02-26 2012-08-23 モール・リサーチ・アプリケーションズ・リミテッド 糖尿病に関連した治療を自動モニタリングする方法およびシステム
US8589082B2 (en) * 2009-08-21 2013-11-19 Neilin Chakrabarty Method for managing obesity, diabetes and other glucose-spike-induced diseases
KR20120102048A (ko) * 2009-09-30 2012-09-17 모르 리서치 애플리케이션즈 리미티드 인슐린 전달의 관리를 위한 모니터링 장치
US20110098548A1 (en) * 2009-10-22 2011-04-28 Abbott Diabetes Care Inc. Methods for modeling insulin therapy requirements
US9089292B2 (en) * 2010-03-26 2015-07-28 Medtronic Minimed, Inc. Calibration of glucose monitoring sensor and/or insulin delivery system
BR112013033254A2 (pt) * 2011-06-23 2017-03-01 Univ Virginia Patent Foundation sistema para gerenciar o controle glicêmico de paciente e meio de armazenamento não transitório legível por computador
EP2873014A4 (de) * 2012-07-11 2016-04-27 Caren Frances Thomson Verfahren, system und vorrichtung zur einstellung von insulindosierungen für diabetiker
US9526834B2 (en) * 2012-08-30 2016-12-27 Medtronic Minimed, Inc. Safeguarding measures for a closed-loop insulin infusion system
EP2897070A1 (de) * 2012-08-30 2015-07-22 Medtronic MiniMed, Inc. Sicherheitsverfahren für ein geschlossenes Insulininfusionssystem
JP2016530905A (ja) * 2013-06-21 2016-10-06 フレゼニウス ヴィアル エスアーエスＦｒｅｓｅｎｉｕｓ Ｖｉａｌ ＳＡＳ 患者へのインスリンの投与を制御する方法及び制御デバイス
CN103605878B (zh) * 2013-08-19 2016-03-30 浙江大学 一种基于数据建模和模型移植的通用血糖预测方法
US20150164414A1 (en) * 2013-12-10 2015-06-18 Grant Matthews Recursive Real-time Determination of Glucose Forcing in a Diabetic patient for use in a Closed Loop Insulin Delivery system
CN104958077A (zh) * 2015-07-24 2015-10-07 珠海福尼亚医疗设备有限公司 一种智能控制的闭环式人工胰腺系统

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272640A1 (en) * 2004-05-13 2005-12-08 Doyle Francis J Iii Method and apparatus for glucose control and insulin dosing for diabetics
US8818782B2 (en) * 2007-06-27 2014-08-26 Roche Diagnostics Operations, Inc. System for developing patient specific therapies based on dynamic modeling of patient physiology and method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017061943A1 *

Also Published As

Publication number Publication date
CN108289642A (zh) 2018-07-17
EP3359039B1 (de) 2021-07-14
EP3359039A1 (de) 2018-08-15
ZA201802977B (en) 2019-07-31
CN108289642B (zh) 2021-02-23
US20180296142A1 (en) 2018-10-18
WO2017061943A1 (en) 2017-04-13
CA3001448A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
ZA201802977B (en) Medical arrangements and a method for determining parameters related to insulin therapy, predicting glucose values and for providing insulin dosing recommendations
EP3364861A4 (de) Transkutane analytsensoren, applikatoren dafür und zugehörige verfahren
IL256999B (en) Diabetes care management consultant
EP3328278A4 (de) Vorrichtung, system und verfahren zur nichtinvasiven überwachung physiologischer parameter
HK1205969A1 (en) Medical microelectrode, method for its manufacture, and use thereof
EP3122254A4 (de) System und verfahren zur anpassung einer therapie je nach mit einem glucosezustand assoziierten risiko
EP2972379A4 (de) System und verfahren für diabetesmanagement auf der basis von glucosemedian, glucoseschwankungen und hypoglykämischem risiko
EP3337390A4 (de) System und verfahren zur gesundheitsüberwachung mit einem nichtinvasiven mehrband-biosensor
EP2995333A4 (de) Herstellungsverfahren für eine vorgefüllte spritze und herstellungsvorrichtung für eine vorgefüllte spritze
EP3179914A4 (de) Verfahren, system und vorrichtung zur kontinuierlichen glucoseüberwachung mit verbesserter genauigkeit
EP3313288A4 (de) Transkutanes lesegerät zur verwendung mit implantierbaren analytsensoren
HK1222117A1 (zh) 用於醫用液體的安瓿和製造安瓿的方法
EP3398633A4 (de) Verabreichungsvorrichtungkonstruktionssystem, verabreichungssystem, verabreichungsvorrichtungkonstruktionsverfahren, verabreichungsvorrichtungkonstruktionsprogramm und konstruktionssystem für medizinische vorrichtung
EP3360469A4 (de) Vorrichtung zur blutdruckmessung und verfahren zur blutdruckmessung damit
EP3190413A4 (de) Verfahren zur vorhersage von arzneimittelalternativen für die behandlung von depression
EP3033001A4 (de) Verfahren und vorrichtung zur vorhersage der notwendigkeit einer bluttransfusion
EP3378511A4 (de) Medizinische pumpe und steuerungsverfahren dafür
EP3101619A4 (de) Arzneimittelverschreibungsunterstützungsverfahren, computerprogramm zur arzneimittelverschreibungsunterstützung und arzneimittelverschreibungsunterstützungsvorrichtung
HK1245049A1 (zh) 用於無創地確定血糖濃度的方法
EP3095476A4 (de) Spritze zur injektion einer wirkstofflösung in die obere hautschicht
SG11201705426VA (en) System and method for adjusting the blood glucose level of a person
EP3131056A4 (de) Verwaltungsverfahren für arzneimittelhistorie, verwaltung für arzneimittelhistorie und programm für arzneimittelhistorie
EP3183361A4 (de) Vorrichtung, system und verfahren zur nichtinvasiven messung von blutglucose
EP3335628A4 (de) Blutdruckanalysevorrichtung, blutdruckmessvorrichtung, blutdruckanalyseverfahren und blutdruckanalyseprogramm
EP3341720A4 (de) Verfahren zur verbesserung der diabetesverwaltung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190411

RIC1 Information provided on ipc code assigned before grant

Ipc: A61B 5/145 20060101AFI20190405BHEP

Ipc: A61M 5/168 20060101ALI20190405BHEP

Ipc: G16H 50/20 20180101ALI20190405BHEP

Ipc: G16H 20/10 20180101ALI20190405BHEP

Ipc: A61K 38/28 20060101ALI20190405BHEP

Ipc: A61B 5/00 20060101ALI20190405BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200908

RIC1 Information provided on ipc code assigned before grant

Ipc: G16H 20/17 20180101ALI20201218BHEP

Ipc: G16H 10/40 20180101ALI20201218BHEP

Ipc: A61K 38/28 20060101ALI20201218BHEP

Ipc: A61M 5/168 20060101ALI20201218BHEP

Ipc: G16H 20/10 20180101ALI20201218BHEP

Ipc: A61B 5/145 20060101AFI20201218BHEP

Ipc: G16H 50/20 20180101ALI20201218BHEP

Ipc: A61B 5/00 20060101ALI20201218BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210202

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602016060736

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1410011

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210815

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1410011

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211014

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211115

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211014

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20211015

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602016060736

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

26N No opposition filed

Effective date: 20220419

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20211031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211007

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211007

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20220914

Year of fee payment: 7

Ref country code: NL

Payment date: 20220922

Year of fee payment: 7

Ref country code: GB

Payment date: 20220915

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220915

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20220919

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20161007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210714